Social Anxiety Disorder (SAD) - Drug Pipeline Landscape, 2023

Social Anxiety Disorder is a significant and persistent fear of social and performance-related situations it is one of the most common mental disorders.

Social Anxiety Disorder is caused by the complex interaction of biological and environmental factors like inherited traits, brain structure (amygdala may play a role in controlling the fear response), and environment.

The main symptoms of social anxiety disorders are a person's inability to work, difficulty maintaining friendships, and family relationships avoiding lifestyle activities like dining out and traveling.

Social anxiety disorder is diagnosed by scale scorings like the liebowitz social anxiety scale, subjective units of distress scale, state-trait anxiety inventory, and negative self-statements during the public speaking subscale (SSPS-N).

Social anxiety disorder is treated by cognitive behavioral therapy and drugs like antidepressants.

Report Highlights

Global Insight Service’s, Social Anxiety Disorders (SAD) - Drug Pipeline Landscape, 2023 report provides an overview of the Social Anxiety Disorders (SAD) pipeline drugs. This report covers detailed insights on Social Anxiety Disorders (SAD) drugs under development, assessment by target, mechanism of action, route of administration and molecule type.Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Social Anxiety Disorders (SAD) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy

Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.

Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.

Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.

Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.